Activation of <scp>PGC</scp> ‐1α via isoliquiritigenin‐induced downregulation of <scp>miR</scp> ‐138‐5p alleviates nonalcoholic fatty liver disease-Reference-Cited by-同舟云学术

Activation of PGC ‐1α via isoliquiritigenin‐induced downregulation of miR ‐138‐5p alleviates nonalcoholic fatty liver disease

Published:2022-01-18 Issue:2 Volume:36 Page:899-913
ISSN:0951-418X
Container-title:Phytotherapy Research
language:en
Short-container-title:Phytotherapy Research

Author:

Wang Lu¹,Wang Xiaohui¹,Kong Lina¹,Li Yingying¹,Huang Kai²,Wu Jingjing¹,Wang Changyuan¹,Sun Huijun¹,Sun Pengyuan¹,Gu Jiangning³,Luo Haifeng³,Liu Kexin¹^ORCID,Meng Qiang¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology College of Pharmacy, Dalian Medical University Dalian China

2. Department of Pharmacology Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University Wuxi China

3. Department of Hepatobiliary Surgery The First Affiliated Hospital of Dalian Medical University Dalian China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ptr.7334

Reference51 articles.

1. Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

2. PGC-1α as a Pivotal Factor in Lipid and Metabolic Regulation

3. Anti-oxidant Constituents of the Roots and Stolons of Licorice (Glycyrrhiza glabra)

4. Gan-Jiang-Ling-Zhu decoction alleviates hepatic steatosis in rats by the miR-138-5p/CPT1B axis

5. New insights into salvianolic acid A action: Regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eriodictyol regulates white adipose tissue browning and hepatic lipid metabolism in high fat diet-induced obesity mice via activating AMPK/SIRT1 pathway;Journal of Ethnopharmacology;2025-01

2. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases;Signal Transduction and Targeted Therapy;2024-03-01

3. Isoliquiritigenin, a potential therapeutic agent for treatment of inflammation-associated diseases;Journal of Ethnopharmacology;2024-01

4. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease;Journal of Physiology and Biochemistry;2023-11-24

5. Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2023-05-23